TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women with a diagnosis diagnosis of Impaired Glucose Tolerance i.e. fasting plasma glucose less than or equal to 125 mg/dl, 2 hour post 75 gram oral glucose tolerance test (OGTT) plasma glucose between 140-199 mg/dl, glycosylated hemoglobin A1c (HbA1c) less than 6.5% as per American Diabetes Association (ADA) criteria.~* Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.~Exclusion Criteria:~* Patients must not be on anti-diabetes therapy for treatment of Impaired Glucose Tolerance (IGT) and must have a fasting plasma glucose concentration less or equal to 125 mg/dl.~* Type 1 or Type 2 diabetes mellitus (fasting plasma glucose greater than 125 mg/dl).~* Patients must not be on or have received metformin, thiazolidinediones, sulfonylureas, DPP IV inhibitor, or exenatide/liraglutide treatment for treatment of IGT at any time. Patients must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications such as hormone replacement therapy with known adverse effects on glucose tolerance levels. Patients taking systemic glucocorticoids will also be excluded.~* Subjects with a history of clinically significant heart disease, peripheral vascular disease, or pulmonary disease.~* Subjects must have a Body Mass Index between 30-35 kg/m2 and stable body weight.~* Subjects must not have clinically significant liver disease (aspartate aminotransferase (AST) \< 2.5 times upper limit of normal, Alanine transaminase (ALT) \< 2.5 times upper limit of normal, Alkaline phosphatase\< 2.5 times upper limit of normal), kidney disease (Serum creatinine \< 1.5 mg/dl in men and 1.4 mg/dl in women) or significant anemia (Hematocrit \< 34 vol%).~* Subjects with a history of any serious hypersensitivity reaction to saxagliptin or a dipeptidyl peptidase 4 (DPP-IV) inhibitor.~* Concomitant treatment with systemic cytochrome P450 3A4 inducers.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 5 mg orally daily for 6 months
- Saxagliptin (Type: EXPERIMENTAL): Saxagliptin 5 mg orally daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AIRVO Device Intervention for Moderate to Severe COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Moderate to severe COPD~  * ≥2 inpatient or outpatient claims (ER, or urgent care included) in the previous calendar year~ * ≥2 COPD exacerbations in previous year~ * Current established care within the Reno/Sparks area~ * Residing in Washoe County or Carson City County~ * Ability to travel to site~ * Willing to use myAirVo™2 for at least four hours per day but preferably ≥7 hours or overnight and be capable of handling the myAirVo™2 device after instruction~ * Prior PFT data available prior to admission into project~ * Understand and accept oral and written information in English~ * Life expectancy greater than 1 year~Exclusion Criteria:~* • End-stage renal disease (ESRD)~  * Comorbidity (known malignant disease, terminal illness, dementia, uncontrolled mental illness, COVID-19)~ * Oxygen requirements greater than 6 L/min~ * Bipap or CPAP use in home~ * Receiving hospice care~ * PCP/PI determines the patient is not a good candidate for project inclusion~ * Lung CA~ * Active smoker status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIRVO Device (Type: EXPERIMENTAL): All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Based on cross-sectional imaging, suspected to have locally advanced/metastatic NSCLC (as determined by the evaluating clinician)~* Scheduled for an appointment in the lung cancer evaluation clinic~Exclusion Criteria:~* Are not suspected to have locally advanced/metastatic NSCLC~* Have a concurrent active malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telehealth (Type: EXPERIMENTAL): Patients in the intervention arm will be scheduled for an enhanced synchronous telehealth visit with a trained lung cancer nurse navigator prior to tissue biopsy. The enhanced synchronous telehealth visit will ideally occur between the initial clinical appointment and diagnostic biopsy (typically a period between two and seven days). In addition to the activities conducted as part of usual care, the nurse navigator will: 1) provide more detailed and individualized education on lung cancer and the rationale for comprehensive molecular testing, including plasma-based tests; and 2) if the patient agrees to testing, pend a default order for plasma-based molecular testing (if not already ordered) for the clinician to sign and arrange for phlebotomy to be performed at the time of the patient's tissue biopsy.
- Usual Care (Type: NO_INTERVENTION): Patients in the usual care arm will receive a telephone call from a trained lung cancer nurse navigator after biopsy, as is typical at Penn Medicine, to 1) review the roles of clinicians on the medical oncology care team; 2) provide brief education on lung cancer; and 3) review the patient's diagnostic history and coordinate collection or completion of imaging required for guideline-recommended cancer staging. At the initial in-person oncology visit, the oncologist may choose to order plasma-based testing if appropriate (and if not already ordered or pending).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Addition of a Vessel Loop in Wound Closure Improve Suture Removal?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective primary CTR (CPT 64721) at Carilion Clinic for carpal tunnel syndrome (CTS) diagnosed by CTS-6 or electrodiagnostic studies (EDS).~Exclusion Criteria:~* Emergency procedures.~* Revision procedures.~* Bilateral procedures.~* Concomitant procedures.~* Inability to provide informed consent for the study.~* Non-native English speakers.~* Allergy to suture material.~* History of wrist trauma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Closure without vessel loop (Type: NO_INTERVENTION): These patients will receive standard of care closure of the carpal tunnel release incision.
- Closure with vessel loop (Type: EXPERIMENTAL): These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Persistent Pulmonary Hypertension of the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent by the parent(s) or the legal representative(s).~2. Term and near term newborns (gestational age \> 34 weeks).~3. Post natal age ≥ 12 hours and \< 7 days.~4. Weight at birth ≥ 2,000 g.~5. Idiopathic PPHN or PPHN due to parenchymal lung disease~6. Documented diagnosis of pulmonary hypertension (PH) confirmed by echocardiography.~7. Need for continued inhaled nitric oxide (iNO) at a dose \> 10ppm after at least 4 hours of continuous iNO treatment.~8. Two oxygenation index (OI) values ≥ 12 taken at least 30 minutes apart, in the 12 hours prior to randomization and while the patient is receiving iNO treatment.~9. Mechanical ventilation with fraction of inspired oxygen (FiO2) ≥ 50% at randomization.~Exclusion Criteria:~1. PH associated with conditions other than PPHN.~2. Immediate need for cardiac resuscitation or extracorporeal membrane oxygenation (ECMO).~3. Lethal congenital anomalies.~4. Congenital Diaphragmatic Hernia.~5. Significant structural cardiac anomalies.~6. Medically significant pneumothorax.~7. Active seizures.~8. Expected duration of mechanical ventilation of less than 48 hours.~9. Mean systemic blood pressure \< 35 mmHg despite therapy with volume infusions and cardiotonic support.~10. Hepatic failure or all conditions with alanine aminotransferase (ALT) values \> 2 x upper limit of normal (ULN).~11. Renal function impairment such as serum creatinine \> 3 x ULN or anuria.~12. Known intracranial hemorrhage grade III or IV.~13. Either hemoglobin or hematocrit level \< 75% of the lower limit of normal (LLN).~14. Thrombocytopenia (platelet count \< 50,000 cells /µL).~15. Leukopenia (WBC \< 2,500 cells/ µL).~16. Any condition precluding the use of a nasogastric/orogastric tube.~17. Administration of prohibited medication prior to randomization.

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bosentan
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Intrapartum Biophysical Profile When Fetal Heart Rate Monitoring is Non-reassuring in Labor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Spontaneous or induced labor~* Gestational ages between 35 - 42 weeks~* Singleton pregnancy~* Intrapartum non-reassuring or uninterpretable FHR tracing defined as any tracing that the Labor and Delivery obstetrician is uncomfortable about or feels does not absolutely provide fetal reassurance. Inclusive FHR patterns will be repetitive late decelerations, recurrent moderate to severe variable decelerations, reduced long or short-term variability, prolonged bradycardia (\<120/min) that resolves, persistent fetal tachycardia (\>160/min for \>60 min,) or any other FHR patterns necessitating further fetal well being evaluation (like scalp pH or scalp stimulation).~Exclusion Criteria:~* Multiple gestation~* Gestational age \< 35 weeks~* Patient denial to undergo ultrasound examination during labor~* Abnormal FHR tracing requiring stat delivery

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of squamous cell carcinoma of the oral cavity~* Able to read and sign and informed consent~Exclusion Criteria:~* Prior mandibular surgery~* Primary intraosseous carcinoma~* Prior history of radiation to the mandible~* Obvious finding of clinical invasion of the mandible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Diagnostic (helical CT, PET/CT, MRI, CBCT) (Type: None): Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects who have, in previous Sangamo clinical trial received SB-728-T or SB-728mR-T, autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases and give consent to participate in the long-term follow-up study.~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Twice-daily Measurement of Expired CO During Hospitalization on Smoking

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized in pneumology for acute respiratory illness or scheduled hospitalization, for a minimum duration of 48h.~* Signature of informed consent~* Patient able to perform all visits and follow the procedures of the study~* Affiliatedor beneficiary of French social security (national health insurance)~Exclusion Criteria:~* Subject who can not read and / or write French~* Expected travel that precludes study completion~* Patient in palliative care~* Inability to maintain apnea more than 8 seconds~* Participation in another clinical trial or administration of an off-label drug within 4 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Twice daily expired CO measurements (Type: EXPERIMENTAL): Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
- Control (Type: ACTIVE_COMPARATOR): Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation Programmes for Scapholunate Instability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages eighteen to sixty,~* wrist pain,~* confirmed scapholunate ligament disruption on MRA or XR (partial or full),~* referred from orthopaedic wrist specialist,~* for conservative management,~* consent to trial.~Exclusion Criteria:~* Under eighteen or over sixty years,~* previous fracture,~* degenerative changes in the wrist,~* previous surgery,~* complex regional pain syndrome or diagnosis of rheumatological conditions,~* no wrist injection in preceding twelve months or other wrist conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- isometric training programme (Type: EXPERIMENTAL): 'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
- isotonic training programme (Type: EXPERIMENTAL): 'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Patent main portal vein with hepatopetal flow~* Bilirubin less than or equal to 2.5 mg/dl, albumin \>2.8g/dl, alkaline phosphatase \<630IU/L, AST \<235IU/L, ALT \<265IU/L, INR \<2.0, PTT \<40sec., absolute neutrophil count \>1K/cumm, platelet count \>100K/cumm~* No encephalopathy~* No previous biliary ductal intervention~* Child A status~* Confirmation of Hepatocellular Carcinoma (through biopsy or radiological exam)~* Unresectable HCC and ineligible for possible curative therapies~* Normal ECG with QT \<480 msec within the previous 2 months~* Normal MUGA scan within the previous 2 months~* Measureable disease per the Response Evaluation Criteria in Solid Tumors (RECIST)~* Subject is competent and willing to provide written informed consent in order to participate in the study~Exclusion Criteria:~* Thrombosis or hepatofugal flow in the main portal vein; presence of a large shunt which in the operator's opinion precludes embolization~* Replacement of greater than 50% of the liver parenchyma by tumor~* Bilirubin greater than or equal to 2.6 mg/dl~* ECOG performance status of 2 or greater~* Previous liver directed therapy~* Previous biliary intervention (excluding cholecystectomy)~* Allergy to iodinated contrast used for angiography~* Elevated creatinine greater than or equal to 1.8 mg/dl~* Women who are pregnant or nursing~* Patients in which any of the following are contraindicated: 1)the use of doxorubicin, 2)MRI or CT scans, 3) Hepatic embolization procedures~* Patients with active bacterial or fungal infection that is deemed to be clinically significant by the investigator~* Patients with cardiac disease, including congestive heart failure, recent myocardial infarction, or uncontrolled arrhythmias~* Non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- doxorubicin-eluting LC Bead (Type: EXPERIMENTAL): transarterial chemoembolization using doxorubicin-eluting LC Beads

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Glucose Monitoring (POC) in the ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* remain 1 week in an ICU~* 18-72 years old~* severe trauma or thermal injury greater than 20% TBSA burn~Exclusion Criteria:~* cerebral arterial injury~* myocardial infarction~* pre-existing renal failure or liver failure~* history of hypoglycemia~* history or high risk of seizures~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- POC Glucose Testing (Type: NO_INTERVENTION): Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
- Continuous Glucose Monitoring (Type: EXPERIMENTAL): Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility